Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Philip A. Philip, MD, PhD, FRCP—Chair, Karmanos Cancer Institute, Wayne State University
Shailesh V. Shrikhande, MD, MS, FRCS—Chair, Tata Memorial Hospital
Abstract 185: Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb, MD
We report a pCR rate of 37.5% (3/8 cases) in the first interim analysis of a phase II pilot trial of perioperative immunotherapy for resectable HCC. Treatment was deemed safe and surgical resection was not delayed. pCR was associated with a significant increase in two clusters of CD8 T-Cell and in Teff/Treg ratio after therapy. The study is ongoing and results may contribute to a paradigm shift in the perioperative treatment of HCC. Clinical trial information: NCT03222076
Abstract 190: Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
First Author: Jonathan R. Strosberg, MD
Data from 107 patients with previously treated NET enrolled in KEYNOTE-158 showed an ORR of 3.7%, including no complete responses and 4 partial responses (3 pancreatic and 1 gastrointestinal <unknown primary>).
Responses were durable, with a median duration of response that had not been reached (range 4.1-15.9+), and 3 of 4 responses ongoing after ≥9 months.
Clinical trial information: NCT02628067
Abstract 191: Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program.
First Author: Michael J. Pishvaian, MD, PhD
The combination of ICI and SBRT is safe and well tolerated in patients with aPDAC.
With a median follow-up of 3.4 months, the median PFS was 2.2 months and median OS was 4.9 months
The overall response rate of 9.6% including 2 patients who achieved a durable partial response lasting over 12 months, suggests meaningful clinical activity. This signifies that ICI and SBRT is a potential new treatment for aPDAC. Clinical trial information: NCT02311361